Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ: KROS )

16.71 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,660
Open 16.71
Bid (Size) 16.58 (1)
Ask (Size) 17.13 (1)
Prev. Close 16.71
Today's Range 16.71 - 16.71
52wk Range 15.67 - 73.00
Shares Outstanding 23,337,862
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
Via ACCESSWIRE
Where Keros Therapeutics Stands With Analysts
Via Benzinga

Performance

YTD
-61.26%
-61.26%
1 Month
-70.47%
-70.47%
3 Month
-70.40%
-70.40%
6 Month
-63.32%
-63.32%
1 Year
-58.47%
-58.47%

More News

Read More
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
Via ACCESSWIRE
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
Via Investor Brand Network
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Via Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
Via Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
Via Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.